Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard.

Won JR, Gao D, Chow C, Cheng J, Lau SY, Ellis MJ, Perou CM, Bernard PS, Nielsen TO.

Mod Pathol. 2013 Nov;26(11):1438-50. doi: 10.1038/modpathol.2013.97. Epub 2013 May 24.

2.

Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.

Marotti JD, Collins LC, Hu R, Tamimi RM.

Mod Pathol. 2010 Feb;23(2):197-204. doi: 10.1038/modpathol.2009.158. Epub 2009 Nov 6.

3.

Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor.

Asleh-Aburaya K, Sheffield BS, Kos Z, Won JR, Wang XQ, Gao D, Wolber R, Gilks CB, Bernard PS, Chia SK, Nielsen TO.

Histopathology. 2017 Jan;70(2):185-194. doi: 10.1111/his.13038. Epub 2016 Sep 29.

PMID:
27402148
4.

Nerve growth factor receptor (NGFR): a potential marker for specific molecular subtypes of breast cancer.

Tsang JY, Wong KH, Lai MW, Lacambra MD, Ko CW, Chan SK, Lam CC, Yu AM, Tan PH, Tse GM.

J Clin Pathol. 2013 Apr;66(4):291-6. doi: 10.1136/jclinpath-2012-201027. Epub 2012 Dec 25.

PMID:
23268325
5.

HER2 status in molecular apocrine breast cancer: associations with clinical, pathological, and molecular features.

Guo W, Wang W, Zhu Y, Zhu X, Shi Z, Wang Y.

Int J Clin Exp Pathol. 2015 Jul 1;8(7):8008-17. eCollection 2015.

6.

The changing role of pathology in breast cancer diagnosis and treatment.

Leong AS, Zhuang Z.

Pathobiology. 2011;78(2):99-114. doi: 10.1159/000292644. Epub 2011 Jun 14. Review.

7.

c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.

Ren X, Yuan L, Shen S, Wu H, Lu J, Liang Z.

Tumour Biol. 2016 Aug;37(8):11385-95. doi: 10.1007/s13277-016-5010-5. Epub 2016 Mar 11.

PMID:
26968553
8.

[Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].

Liu H, Fan QH, Zhang ZH, Li X, Yu HP, Liu GZ, Meng FQ.

Zhonghua Bing Li Xue Za Zhi. 2009 Jan;38(1):23-8. Chinese.

PMID:
19489221
9.

P-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study.

Sousa B, Paredes J, Milanezi F, Lopes N, Martins D, Dufloth R, Vieira D, Albergaria A, Veronese L, Carneiro V, Carvalho S, Costa JL, Zeferino L, Schmitt F.

Histol Histopathol. 2010 Aug;25(8):963-74. doi: 10.14670/HH-25.963.

PMID:
20552547
10.

Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype.

Lu S, Singh K, Mangray S, Tavares R, Noble L, Resnick MB, Yakirevich E.

Mod Pathol. 2013 Apr;26(4):485-95. doi: 10.1038/modpathol.2012.187. Epub 2012 Dec 7.

11.

Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.

Fedele CG, Ooms LM, Ho M, Vieusseux J, O'Toole SA, Millar EK, Lopez-Knowles E, Sriratana A, Gurung R, Baglietto L, Giles GG, Bailey CG, Rasko JE, Shields BJ, Price JT, Majerus PW, Sutherland RL, Tiganis T, McLean CA, Mitchell CA.

Proc Natl Acad Sci U S A. 2010 Dec 21;107(51):22231-6. doi: 10.1073/pnas.1015245107. Epub 2010 Dec 2.

12.

Molecular subtyping of male breast cancer by immunohistochemistry.

Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ, van der Groep P, Hinrichs B, van Diest PJ.

Mod Pathol. 2012 Mar;25(3):398-404. doi: 10.1038/modpathol.2011.174. Epub 2011 Nov 4.

13.

How basal are triple-negative breast cancers?

Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P, Birnbaum D.

Int J Cancer. 2008 Jul 1;123(1):236-40. doi: 10.1002/ijc.23518.

14.

Salivary gland-like tumors of the breast express basal-type immunohistochemical markers.

Reyes C, Jorda M, Gomez-Fernández C.

Appl Immunohistochem Mol Morphol. 2013 Jul;21(4):283-6. doi: 10.1097/PAI.0b013e31826a277e. Review.

PMID:
22935826
15.

Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco.

El Fatemi H, Chahbouni S, Jayi S, Moumna K, Melhouf MA, Bannani A, Mesbahi O, Amarti A.

Diagn Pathol. 2012 Dec 7;7:170. doi: 10.1186/1746-1596-7-170. Retraction in: Diagn Pathol. 2013;8:127.

16.

Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.

Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, Richardson AL, Schnitt SJ, Garber JE.

Am J Surg Pathol. 2009 Jul;33(7):1093-7. doi: 10.1097/PAS.0b013e31819c1c93.

PMID:
19390427
17.

Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.

Nassar A, Sussman ZM, Lawson D, Cohen C.

Breast J. 2012 Sep;18(5):399-405. doi: 10.1111/j.1524-4741.2012.01279.x. Epub 2012 Aug 10.

PMID:
22882580
18.

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO.

Clin Cancer Res. 2008 Mar 1;14(5):1368-76. doi: 10.1158/1078-0432.CCR-07-1658.

19.

Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.

Bhargava R, Beriwal S, Striebel JM, Dabbs DJ.

Appl Immunohistochem Mol Morphol. 2010 Mar;18(2):113-8. doi: 10.1097/PAI.0b013e3181b94ff1.

PMID:
19801938
20.

Clinicopathological and molecular significance of Sumolyation marker (ubiquitin conjugating enzyme 9 (UBC9)) expression in breast cancer of black women.

Agboola AO, Musa AA, Ayoade BA, Banjo AA, Anunobi CC, Deji-Agboola AM, Rakha EA, Nolan C, Ellis IO, Green AR.

Pathol Res Pract. 2014 Jan;210(1):10-7. doi: 10.1016/j.prp.2013.09.011. Epub 2013 Oct 8.

PMID:
24176171

Supplemental Content

Support Center